Biotech pauses trial after second patient death linked to gene therapy

Sarepta Therapeutics reported a second patient death linked to acute liver failure following treatment with its $3.2 million Duchenne muscular dystrophy gene therapy, Elevidys, raising concerns about the drug's safety profile. The FDA, which initially granted accelerated approval to Elevidys based on limited evidence, is treating the situation with the highest level of concern and will take appropriate regulatory actions. Sarepta is pausing a clinical trial and convening experts to mitigate the risk of liver failure, as the deaths prompt a reevaluation of the risk-benefit calculation for patients and families facing the fatal disease.

Analysis

Sarepta Therapeutics (SRPT) faces intensified scrutiny following a second patient death attributed to acute liver failure after receiving its $3.2 million Duchenne muscular dystrophy gene therapy, Elevidys. This therapy generated approximately $821 million in revenue for Sarepta last year from over 900 patients treated. The FDA, which initially granted Elevidys accelerated approval in 2023 and controversially expanded its approval in June 2024 despite a clinical trial failing its primary measure and pre-existing concerns from agency staff regarding liver failure risks, is now reviewing the situation with the "highest level of concern." In response, Sarepta has paused a clinical trial, with FDA concurrence, and is forming an independent expert panel to discuss an immune suppression regimen to mitigate liver injury risk. These events have prompted patient advocacy groups to state that the risk-benefit calculation for Elevidys has "changed markedly," reflecting the grave implications for a patient population with a progressive, fatal disease. The "strongly negative" sentiment (-0.8 general, -0.85 for SRPT) and "high" market impact score (0.75) underscore the substantial headwinds for the company.

Key Decisions for Investors

• Investors should closely monitor upcoming FDA communications and potential regulatory actions regarding Elevidys, as these could materially impact its approved indications, utilization, and Sarepta's revenue stream.
• A thorough reassessment of Sarepta's revenue forecasts for Elevidys is warranted, considering the increased safety concerns which may lead to reduced physician and patient uptake, alongside potential liabilities and increased R&D expenditure for safety management.
• Given the critical nature of these adverse events for Sarepta's key revenue driver, investors should prepare for heightened stock volatility and re-evaluate their risk tolerance regarding SRPT, particularly noting the FDA's previous controversial approval decisions and the current intense scrutiny.